

Antimicrobials for Multi-drug Resistant Gram Negative Bacilli (MDR GNB) & Availability in AHS

Antimicrobial Agent ¹	Activity	AHS acute care hospital Formulary Status/ Availability/Cost	Contact Information
Cefiderocol (Fetroja)	CRE CPE CRPA (incl. MBL) CRAB SM	SAP⁴ Very laborious acquisition process and expensive: \$190 USD/1g + ~ \$1,878 USD shipping	As of Dec 1, 2021, SAP requests are processed through Inceptua via Imap portal: https://inceptua.com Shionogi 1-800-849-9707 medinfo@shionogi.com
Ceftazidime-avibactam (Avycaz) 2.5 g	CRE Class A + D CPE CRPA (non-MBL)	SAP⁴ Sep 2020 - Not available due to a back order that is not expected to be resolved until sometime in 2022 (confirmed still on backorder April 2022).	AbbVie Primary contact: Foo-Lim Yeh (Director, Regulatory Affairs): foolim.yeh@abbvie.com Secondary contact: Rhiannon Konig (Senior Manager, Regulatory Affairs): rhiannon.konig@abbvie.com 1-800-668-6424 ext 7353, Cell 416-435-2974 Email:MR-MedicalInformation@abbvie.com
Ceftolozane-tazobactam (Zerbaxa) 1.5 g vials contain ceftolozane 1 g/ tazobactam 0.5 g	CRE (non-CPP) CRPA (non-CPP) SM	FRG \$142.80/1.5g	Merck
Fosfomycin IV (Ivozfo)	CRE CPE CRPA (incl. MBL)	NF – STEDT \$19/gram	Verity Pharmaceuticals Contact: Summer Stewart, s.stewart@veritypharma.com
Imipenem-relebactam (Recarbrio) 1.25g vial contains imipenem 500mg/cilastatin 500mg/relebactam 250mg	CRE Class A + D CPE CRPA (non-MBL)	SAP⁴ No charge	Merck 1-800-463-7251 regulatoryaffairs_canada@merck.com
Meropenem-vaborbactam (Vabomere)	CRE Class A CPE	Jan 2022 - No SAP process in place , per Melinta	Melinta Therapeutics
Plazomicin (Zemdri)	CRE CPE CRPA (incl. MBL)	Unavailable \$315USD/500 mg	Cipla USA Courtney.Barton@Cipla.com

Antimicrobials for MDR GNB & Availability in AHS | 2

Antimicrobial Agent ¹	Activity	AHS acute care hospital Formulary Status/ Availability/Cost	Contact Information
Colistin	CRE ² CPE ² CRPA CRAB	F \$12.49/150mg	FRESENIUS KABI
Tigecycline (Tygacil)	CRE ³ CPE ³ CRAB SM	FRG Restricted to Infectious Diseases \$17.50/50mg	Pfizer

1. Susceptibility testing available for all of these agents, except fosfomycin IV for non-*E. coli* Enterobacterales. Contact microbiology lab.
2. Intrinsic resistance of: *Proteus* species, *Providencia* species, *Morganella morganii*, *Serratia marcescens*
3. Intrinsic resistance of: *Proteus* species, *Providencia* species, *Morganella morganii*
4. Special Access Programme contact information:
 Website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html>
 Phone: (613) 941-2108 (Must press 0 to reach an on-call officer)
 Fax: (613) 941-3194
 E-mail: SAPdrugs@hc-sc.gc.ca

CPE = carbapenemase-producing *Enterobacterales*
 Class A CPE – includes KPC, GES, NMC, SME, IMI carbapenemases
 Class D CPE – includes OXA carbapenemases

CPP: carbapenemase producer

CRAB = carbapenem-resistant *Acinetobacter baumannii*

CRE = carbapenem-resistant *Enterobacterales*

CRPA = carbapenem-resistant *Pseudomonas aeruginosa*

F = formulary

FRG = formulary, restricted with guidelines

MBL: metallo-β-lactamase

NF = non-formulary

SAP = Special Access Programme request

SM = *Stenotrophomonas maltophilia*

STEDT = Short Term Exceptional Drug Therapy request

Acknowledgments: Christine Ondro PharmD; Tanis Dingle MD; Susan Fryters BScPharm, ACPR

Reviewed by AHS Antimicrobial Stewardship Subcommittee, March 26, 2021

Approved by AHS Antimicrobial Stewardship Subcommittee, May 28, 2021

Last updated: May 10, 2022